Caribou Biosciences (NASDAQ:CRBU) is a biotechnology company focused on revolutionizing healthcare through the development of CRISPR-based technology platforms for genome editing. With a strong commitment to innovation, Caribou is actively pursuing a diverse range of projects aimed at developing therapeutic treatments that can address unmet medical needs across various diseases. The company is at the forefront of utilizing CRISPR-Cas systems to engineer cell therapies with the potential to deliver life-changing benefits to patients. As part of its objectives, Caribou is dedicated to advancing its pipeline of products through rigorous scientific research, while upholding the highest standards of quality and ethical considerations in gene editing.